INHIBITORY EFFECTS OF SCHISANDRIN A AND SCHISANDRIN B ON CYP3A ACTIVITY

被引:25
|
作者
Li, W. L. [1 ]
Xin, H. W. [1 ]
Su, M. W. [1 ]
Xiong, L. [1 ]
机构
[1] Wuhan Gen Hosp Guangzhou Command, Dept Clin Pharmacol, Wuhan 430070, Peoples R China
关键词
IN-VITRO; P-GLYCOPROTEIN; SPHENANTHERA EXTRACT; MULTIDRUG-RESISTANCE; LIVER-MICROSOMES; ORGANIC-SOLVENTS; MIDAZOLAM; DRUGS; PHARMACOKINETICS; METABOLISM;
D O I
10.1358/mf.2010.32.3.1434161
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Our aim was to investigate the inhibitory effects of schisandrin A and schisandrin Ban cytochrome P450 (CYP3A) activity in rat liver microsomes and the mechanism of this interaction. 1'-Hydroxy midazolam and midazolam 1-hydroxylation catalyzed by CYP3A were analyzed by high performance liquid chromatography (HPLC). Results showed that schisandrin A and schisandrin B inhibited CYP3A activity with IC50 values of 6.60 and 5.51 mu M and K-i Values of 5.83 and 4.24 mu M, respectively. A dilution assay plot of each inhibitor gave a slope value of up to 91% that of the control samples. The inactivation of CYP3A activity by schisandrin A and schisandrin B was found to be both time- and concentration-dependent (schisandrin A: K-i = 4.51 mu M, K-inact = 0.134/min; schisandrin B: K-i = 3.01 mu M, K-inact = 0.112/min). We conclude that the inhibition of CYP3A activity in rat liver microsomes by schisandrin A and schisandrin B is mostly attributed to a mixed noncompetitive and complete inhibition.
引用
收藏
页码:163 / 169
页数:7
相关论文
共 50 条
  • [21] Evaluation of neuroactive effects of ethanol extract of Schisandra chinensis, Schisandrin, and Schisandrin B and determination of underlying mechanisms by zebrafish behavioral profiling
    WANG Jia-Wei
    LIANG Feng-Yin
    OUYANG Xiang-Shuo
    LI Pei-Bo
    PEI Zhong
    SU Wei-Wei
    Chinese Journal of Natural Medicines, 2018, 16 (12) : 916 - 925
  • [22] Simultaneous Quantification of Schisandrin, Deoxyschisandrin and Schisandrin B in Rat Bile, Urine, and Feces and Application to Excretion Study
    Ji, De
    Liu, Jing
    Li, Lin
    Mao, Chunqin
    Yin, Fangzhou
    Lu, Tulin
    LATIN AMERICAN JOURNAL OF PHARMACY, 2014, 33 (05): : 797 - 803
  • [23] Determination of Schisandrin A and Schisandrin B in Traditional Chinese Medicine Preparation Huganpian Tablet by RP-HPLC
    Yu, Bingsheng
    Sheng, Dongdi
    Tan, Qiumin
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2019, 67 (07) : 713 - 716
  • [24] Schisandrin B and Schisandrol B induce mouse CYP2b10 associated with CAR not PXR
    Xie, Minzhu
    Lin, Jiao
    Kang, Jinyu
    Zheng, Xiuting
    Fang, Kailu
    Luo, Yishuang
    Liu, Aiming
    Yang, Julin
    PHYTOCHEMISTRY LETTERS, 2020, 35 : 164 - 170
  • [25] Comparative Effects of Schisandrin A, B, and C on Acne-Related Inflammation
    Guo, Miaomiao
    An, Faliang
    Wei, Xing
    Hong, Minhua
    Lu, Yanhua
    INFLAMMATION, 2017, 40 (06) : 2163 - 2172
  • [26] Comparative Effects of Schisandrin A, B, and C on Acne-Related Inflammation
    Miaomiao Guo
    Faliang An
    Xing Wei
    Minhua Hong
    Yanhua Lu
    Inflammation, 2017, 40 : 2163 - 2172
  • [27] AhR and PPARα:: antagonistic effects on CYP2B and CYP3A, and additive inhibitory effects on CYP2C11
    Shaban, Z
    Soliman, M
    El-Shazly, S
    El-Bohi, K
    Abdelazeez, A
    Kehelo, K
    Kim, HS
    Muzandu, K
    Ishizuka, M
    Kazusaka, A
    Fujita, S
    XENOBIOTICA, 2005, 35 (01) : 51 - 68
  • [28] Inhibitory effect of schisandrin on spontaneous contraction of isolated rat colon
    Yang, Jiaming
    Lp, Paul S. P.
    Yeung, John H. K.
    Che, Chun-Tao
    PHYTOMEDICINE, 2011, 18 (11) : 998 - 1005
  • [29] Inhibitory Effects of Baicalin on the Expression and Activity of CYP3A Induce the Pharmacokinetic Changes of Midazolam in Rats
    Tian, Xin
    Cheng, Zhen-Yu
    Jin, Han
    Gao, Jie
    Qiao, Hai-Ling
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [30] The inhibitory effect of intestinal bacterial metabolite of ginsenosides on CYP3A activity
    Liu, Y
    Li, W
    Li, P
    Deng, MC
    Yang, SL
    Yang, L
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (10) : 1555 - 1560